Cancer Research UK Commercial Partnerships United Kingdom


Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. Our specialist Commercial Partnerships Team advance discoveries to beat cancer by translating promising scientific research into attractive commercial propositions. With exclusive rights to more than £350m of world-class cancer research a year from the Cancer Research UK network and beyond, we are the gateway to much of the high quality oncology research happening in the UK today. We work closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners.
 
We develop promising ideas into successful cancer therapeutics, software, devices, diagnostics and enabling technologies. We currently have more than 30 partnered agents in pre-clinical and clinical development and five drugs already on the market and benefiting patients: Temodal, Zytiga, Erivedge, Lynparza and Rubraca.
 
Our Clinical Development Partnerships (CDP) scheme, run by Cancer Research UK’s Centre for Drug Development, works with leading pharmaceutical and biotechnology companies to progress the development of new agents that may otherwise be delayed in development.  Since its establishment 10 years ago, the scheme has seen 20 treatments enter the program, with 13 projects currently in active development.
Dr David Kennard
Senior Advisor 
Dr Toby Richardson
Associate Director Business Development 

Chronos Therapeutics United Kingdom

Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system.

Dr Huw Jones
CEO 
Dr Helen Kuhlman
VP Corporate Development 

CIMYM BioSciences Ltd United Kingdom

CIMYM BioSciences was established to develop oncology and immunological therapeutics.  At CIMYM we believe passionately that drug development can only be successful if it is patient centred; ‘Begin with the patient in mind…’
As a healthcare company we recognise an exceptional idea to fill a medical need, build a network and then establish a clinical utility that will improve patient care.  CIMYM uses its expertise to manage value-enhancing activities in the development process of pharmaceuticals and diagnostics. It takes a patient-centred approach to co-develop innovative products and in turn licenses the rights for manufacture and marketing to other pharmaceutical companies for license fees and royalty payments.
CIMYM BioSciences attendance at Bio-Europe will provide a springboard to establish business contacts within the US, European and Asian Biotech markets.
Ms Yvonne Joseph
Ms Yvonne Joseph
Managing Director 

Clinical Network Services (UK) United Kingdom

Clinical Network Services (CNS) is an integrated service group focused on product development and has offices in Australia, New Zealand, the UK and the USA.  CNS creates value for small-medium sized biotechnology companies by progressing early stage products into phase 1 & 2 clinical trials or the marketplace sooner.  CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical services and biometrics team.  CNS’ regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval. 

CNS offers a uniquely differentiated, customer-orientated suite of services to clients which enables CNS to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.

Mr Paul Cronin
Director 
Mr Russell Neal
Managing Director 

Cresset Discovery Services United Kingdom

Cresset Discovery Services manages and delivers outsourced computational chemistry programs. Our consultants work alongside your chemists to solve problems, provide fresh ideas, remove roadblocks and add direction and insight. We help you reach your next milestone faster and more cost effectively.

Computational chemistry helps your chemists understand as much as possible about the systems they are working on. This makes it easier to direct your resources in the direction most likely to succeed, saving you time and money.

Every client brings a different approach, new science and a fresh way of working. We propose methods that provide answers in the most intelligent and innovative way we can. Collaboration often sparks new and better methods and ideas, through new challenges and by the synergistic nature of contract research.

We have extensive industry experience and a proven track record working on over 200 projects over the last decade with many leading pharmaceutical, biotech, agrochemical, flavor and fragrance companies.

Our discovery services are flexible. By accessing expertise where and when you need it you eliminate unnecessary overheads while obtaining a world class service. Use us as your long term CRO or to help navigate bottlenecks in your project.

Organisation type
Dr Ritesh Chauhan
Account Manager 

Crystec United Kingdom

Crystec applies the latest supercritical fluid (SCF) technology to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec’s modified supercritical anti-solvent (mSAS) technology can be applied to small and large drug molecules in a range of dosage forms.

Our services include crystal form screening and particle design (including composite particles and co-crystals), addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. Our process is scaled to GMP manufacturing levels. We are also engaged in in-house programmes to develop improved products and currently have licensing opportunities available in several therapeutic areas, including urge incontinence and fungal infections.

The first product based on SCF technology is expected to launch this year. It is an inhaled product for migraine, exploiting the benefits SCF processing brings to enable exceptional particle size control and deep lung deposition. The particle design and scale-up to GMP for this product were managed by members of the Crystec team.

If you are interested in understanding how mSAS could accelerate your product development, contact us for more information – emily.bevis@crystecpharma.com

Organisation type
Ms Catherine Hunter
Business Development Director